Intech Biopharm Corp (益得生技) has started testing the effects of a metered-dose inhaler generic of Teva Pharmaceutical Industries Ltd’s ProAir, and expects to gain marketing approval by 2023, it said yesterday.
The company, which developed SYN011 to treat acute asthma, received approval from the US Food and Drug Administration in August to study the biochemical and physiological effects of the drug in a phase 3 clinical trial, Intech spokesperson Hugues Hung (洪堯國) told the Taipei Times.
The company has recruited about 200 participants with asthma for the test, dividing them into control and experiment groups to receive a placebo, a brand name drug and SYN011, to determine whether SYN001’s efficacy is comparable to that of a brand name drug, Hung said.
Photo: CNA
“We have to give participants some food containing allergens that can trigger asthma symptoms. We will see how the inhaler relieves the symptoms,” Hung said.
The study is to finish by the end of next year, and Intech plans to apply to the US agency for marketing approval in the first quarter of 2023, he said.
Intech is optimistic about the metered-dose inhalers market in the US, where the health regulator has become more open to generics amid the COVID-19 pandemic, he said.
Prior to the pandemic, the agency never approved generic versions of metered-dose inhalers, although some applicants had completed trials, Hung said.
As the pressurized metered-dose inhalers could be used to help relieve respiratory symptoms of people with COVID-19, the US regulator last year became more open, granting approvals to India-based Cipla Ltd and Lupin Ltd, which offer generic versions of Merck Sharp & Dohme Ltd’s (MSD) Proventil and Teva’s ProAir respectively, he said.
Last year, Cipla sold about 3 million inhalers and Lupin sold 1 million at lower prices than those of brand names, or at a discount of between 50 and 60 percent, Hung said.
Sales of MSD’s and Teva’s drugs were not affected by the generic versions, and they even raised their prices, suggesting there is a growing demand for the drug in the market, he said.
Intech expects to be the latest supplier of metered-dose inhalers using salbutamol as the main ingredient, which is used to relieve symptoms of asthma, after GlaxoSmithKline PLC, MSD, Teva and the two Indian firms, Hung said.
“With this market position, we will likely gain a market share of 10 to 20 percent,” he said.
More than 64 million metered-dose inhalers using salbutamol were sold in the US last year, Hung said, adding that a larger market share would help boost Intech’s revenue.
JITTERS: Nexperia has a 20 percent market share for chips powering simpler features such as window controls, and changing supply chains could take years European carmakers are looking into ways to scratch components made with parts from China, spooked by deepening geopolitical spats playing out through chipmaker Nexperia BV and Beijing’s export controls on rare earths. To protect operations from trade ructions, several automakers are pushing major suppliers to find permanent alternatives to Chinese semiconductors, people familiar with the matter said. The industry is considering broader changes to its supply chain to adapt to shifting geopolitics, Europe’s main suppliers lobby CLEPA head Matthias Zink said. “We had some indications already — questions like: ‘How can you supply me without this dependency on China?’” Zink, who also
The number of Taiwanese working in the US rose to a record high of 137,000 last year, driven largely by Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) rapid overseas expansion, according to government data released yesterday. A total of 666,000 Taiwanese nationals were employed abroad last year, an increase of 45,000 from 2023 and the highest level since the COVID-19 pandemic, data from the Directorate-General of Budget, Accounting and Statistics (DGBAS) showed. Overseas employment had steadily increased between 2009 and 2019, peaking at 739,000, before plunging to 319,000 in 2021 amid US-China trade tensions, global supply chain shifts, reshoring by Taiwanese companies and
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) received about NT$147 billion (US$4.71 billion) in subsidies from the US, Japanese, German and Chinese governments over the past two years for its global expansion. Financial data compiled by the world’s largest contract chipmaker showed the company secured NT$4.77 billion in subsidies from the governments in the third quarter, bringing the total for the first three quarters of the year to about NT$71.9 billion. Along with the NT$75.16 billion in financial aid TSMC received last year, the chipmaker obtained NT$147 billion in subsidies in almost two years, the data showed. The subsidies received by its subsidiaries —
At least US$50 million for the freedom of an Emirati sheikh: That is the king’s ransom paid two weeks ago to militants linked to al-Qaeda who are pushing to topple the Malian government and impose Islamic law. Alongside a crippling fuel blockade, the Group for the Support of Islam and Muslims (JNIM) has made kidnapping wealthy foreigners for a ransom a pillar of its strategy of “economic jihad.” Its goal: Oust the junta, which has struggled to contain Mali’s decade-long insurgency since taking power following back-to-back coups in 2020 and 2021, by scaring away investors and paralyzing the west African country’s economy.
RSS